title: Natural course of serum-specific immunoglobulin E and immunoglobulin G4 for a span of eight years in untreated patients with perennial allergic rhinitis.
abstract: During the past two decades, considerable attention has been devoted to the clinical role of serum-specific IgE and IgG4 following immunotherapy. To definitely discuss the clinical role of serum-specific IgG4, we should know the natural course of serum-specific IgG4 in the untreated patient with allergic rhinitis. To our knowledge, however, no such kind of study can be found in the literature. Our present study focused on the long-term follow-up of serum-specific IgE and IgG4 in patients who were not treated with immunotherapy for perennial allergic rhinitis. They were scheduled to take no medication for their perennial nasal symptoms for 8 years. Serum-specific IgE and IgG4 in untreated patients with perennial allergic rhinitis never significantly change during the observation period. These data will be of great value for studies in serologic changes following active treatment for atopic diseases. Additionally, our study suggests that a reduction in serum-specific IgE and an increase in serum-specific IgG4 following immunotherapy are not the result of an immunotherapy-independent and age-related phenomenon but the result of active immunologic modulation by immunotherapy.
authors.affiliation: Department of Otolaryngology, Osaka City University Medical School, Osaka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Y
authors.initials: Y
authors.lastname: Nakai
authors.forename: Y
authors.initials: Y
authors.lastname: Ohno
authors.forename: H
authors.initials: H
authors.lastname: Okamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kakinoki
authors.forename: T
authors.initials: T
authors.lastname: Masamoto
authors.forename: A
authors.initials: A
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Hayashi
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000485:Allergens / Q000276:immunology; D000818:Animals; D039741:Antigens, Dermatophagoides; D005260:Female; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy; D007073:Immunoglobulin E / Q000097:blood*; D007074:Immunoglobulin G / Q000097:blood*; D007167:Immunotherapy; D016233:Immunotherapy, Active; D008137:Longitudinal Studies; D008297:Male; D008925:Mites / Q000276:immunology; D011058:Pollen / Q000276:immunology; D012221:Rhinitis, Allergic, Perennial / Q000097:blood / Q000276:immunology* / Q000628:therapy; D014197:Trees
chemical_list: D000276:Adjuvants, Immunologic; D000485:Allergens; D039741:Antigens, Dermatophagoides; D006023:Glycoproteins; D007074:Immunoglobulin G; D007073:Immunoglobulin E